Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)

Stephan von Haehling, Mitja Lainscak, Wolfram Doehner, Piotr Ponikowski, Giuseppe Rosano, Jens Jordan, Piotr Rozentryt, Mathias Rauchhaus, Rostislav Karpov, Vsevolod Tkachuk, Yelena Parfyonova, Andrey Y Zaritskey, Eugeniy V Shlyakhto, John G Cleland, Stefan D Anker, Stephan von Haehling, Mitja Lainscak, Wolfram Doehner, Piotr Ponikowski, Giuseppe Rosano, Jens Jordan, Piotr Rozentryt, Mathias Rauchhaus, Rostislav Karpov, Vsevolod Tkachuk, Yelena Parfyonova, Andrey Y Zaritskey, Eugeniy V Shlyakhto, John G Cleland, Stefan D Anker

Abstract

BACKGROUND: Chronic heart failure (CHF) is increasing in prevalence. Patients with CHF usually have co-morbid conditions, but these have been subjected to little research and consequently there is a paucity of guidance on how to manage them. Obesity and diabetes mellitus are common antecedents of CHF and often complicate management and influence outcome. Cachexia is an ominous and often missed sign in patients with CHF. METHODS: This manuscript describes the rationale and the design of Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF), a prospective, multicentre, multinational, longitudinal, pathophysiological evaluation study, which is being conducted in 11 centres across six countries in the European Union and in Russia. We aim to recruit >1,600 patients with CHF due to various common aetiologies, irrespective of left ventricular ejection fraction, and with or without co-morbidities at study entry. In addition, >300 patients with type 2 diabetes mellitus without CHF and >150 healthy subjects will serve as control groups. Participants will be systematically investigated at annual intervals for up to 48 months. Additional investigations focusing on cellular and subcellular mechanisms, adipose and skeletal muscle tissue, and in endothelial progenitor cells will be performed in selected subgroups. CONCLUSIONS: SICA-HF will provide insights into common co-morbidities in CHF with a specific emphasis on diabetes mellitus and body mass. This will provide a more thorough pathophysiological understanding of the complexity of CHF that will help develop therapies tailored to manage specific co-morbidities.

Figures

Fig. 1
Fig. 1
Participating centres in SICA-HF
Fig. 2
Fig. 2
Overview of SICA-HF

References

    1. European Society of Cardiology. Heart Failure Association of the ESC (HFA) European Society of Intensive Care Medicine (ESICM) Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Tendera M, Auricchio A, Bax J, Böhm M, Corrà U, della Bella P, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW, Zamorano JL, Zannad F. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail. 2008;10:933–989. doi: 10.1016/j.ejheart.2008.08.005.
    1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O’Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee And Stroke Statistics Subcommittee. Circulation. 2009;119:e21–181. doi: 10.1161/CIRCULATIONAHA.108.191261.
    1. Meerding WJ, Bonneux L, Polder JJ, Koopmanschap MA, van der Maas PJ. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. BMJ. 1998;317:111–115.
    1. O’Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13:S107–S112.
    1. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000;83:596–602. doi: 10.1136/heart.83.5.596.
    1. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–2448. doi: 10.1056/NEJMoa0908355.
    1. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, POSH Investigators Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH) Eur Heart J. 2006;27:1216–1222. doi: 10.1093/eurheartj/ehi859.
    1. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, Coats AJ. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526–534.
    1. Khand AU, Rankin AC, Kaye GC, Cleland JG. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J. 2000;21:614–632. doi: 10.1053/euhj.1999.1767.
    1. Calvert MJ, Freemantle N, Yao G, Cleland JG, Billingham L, Daubert JC, CARE-HF investigators Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J. 2005;26:2681–2688. doi: 10.1093/eurheartj/ehi662.
    1. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase] Eur Heart J. 2006;27:1928–1932. doi: 10.1093/eurheartj/ehl099.
    1. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317–327. doi: 10.1016/j.jacc.2003.07.046.
    1. Banerjee P, Clark AL, Cleland JG. Diastolic heart failure: a difficult problem in the elderly. Am J Geriatr Cardiol. 2004;13:16–21. doi: 10.1111/j.1076-7460.2004.01940.x.
    1. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1:1–5. doi: 10.1007/s13539-010-0002-6.
    1. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–1053. doi: 10.1016/S0140-6736(96)07015-8.
    1. Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, Clark AL, Anker SD. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail. 2003;9:29–35. doi: 10.1054/jcaf.2003.4.
    1. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38:789–795. doi: 10.1016/S0735-1097(01)01448-6.
    1. Oreopoulos A, Padwal R, McAlister FA, Ezekowitz J, Sharma AM, Kalantar-Zadeh K, Fonarow GC, Norris CM. Association between obesity and health-related quality of life in patients with coronary artery disease. Int J Obes. 2010;34:1434–1441. doi: 10.1038/ijo.2010.73.
    1. Badheka AO, Rathod A, Kizilbash MA, Garg N, Mohamad T, Afonso L, Jacob S. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med. 2010;123:646–651. doi: 10.1016/j.amjmed.2009.11.026.
    1. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology The EuroHeart failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–463. doi: 10.1016/S0195-668X(02)00823-0.
    1. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, Rodeheffer RJ, Roger VL. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119:591–599. doi: 10.1016/j.amjmed.2006.05.024.
    1. Kamalesh M, Nair G. Disproportionate increase in prevalence of diabetes among patients with congestive heart failure due to systolic dysfunction. Int J Cardiol. 2005;99:125–127. doi: 10.1016/j.ijcard.2004.05.049.
    1. Goode KM, John J, Rigby AS, Kilpatrick ES, Atkin SL, Bragadeesh T, Clark AL, Cleland JG. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart. 2009;95:917–923. doi: 10.1136/hrt.2008.156646.
    1. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005;46:1019–1026. doi: 10.1016/j.jacc.2005.02.093.
    1. Lenks K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2010;1:9–21. doi: 10.1007/s13539-010-0007-1.
    1. Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, Anker SD. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle. 2010;1:35–42. doi: 10.1007/s13539-010-0008-0.
    1. von Haehling S, Doehner W, Anker SD. Nutrition, metabolism and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2007;73:298–309. doi: 10.1016/j.cardiores.2006.08.018.
    1. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121:227–252. doi: 10.1016/j.pharmthera.2008.09.009.
    1. Lenzen MJ, Rosengren A, op Reimer WJ Scholte, Follath F, Boersma E, Simoons ML, Cleland JG, Komajda M. Management of patients with heart failure in clinical practice: differences between men and women. Heart. 2008;94:e10. doi: 10.1136/hrt.2006.099523.
    1. Szabo T, von Haehling S, Hadebank D, Rauchhaus M, Lainscak M, Sandek A, Schefold J, Anker SD, Doehner W. Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure. Int J Cardiol. 2009. doi:10.1016/j.ijcard.2009.07.030.
    1. Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med. 1999;160:1101.
    1. von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1973–1980. doi: 10.1016/j.jacc.2007.08.012.
    1. Jong P, McKelvie R, Yusuf S. Should treatment for heart failure with preserved ejection fraction differ from that for heart failure with reduced ejection fraction? BMJ. 2010;341:c4202. doi: 10.1136/bmj.c4202.
    1. Kapoor JR, HEidenreich PA. Obesity and survival in patients with heart failure and preserved systolic function: a U-shaped relationship. Am Heart J. 2010;159:75–80. doi: 10.1016/j.ahj.2009.10.026.
    1. Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B. Comparison of patients with heart failure and preserved ejection fraction among those with versus without diabetes. Am J Cardiol. 2010;105:373–377. doi: 10.1016/j.amjcard.2009.09.041.
    1. Roberts AW, Clark AL, Witte KK. Review article: left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease—do we need to screen our patients? Diab Vasc Dis Res. 2009;6:153–163. doi: 10.1177/1479164109338774.
    1. Hassan SA, Deswal A, Bozkurt B, Aguilar D, Mann DL, Pritchett AM. The metabolic syndrome and mortality in an ethnically diverse heart failure population. J Card Fail. 2008;14:590–595. doi: 10.1016/j.cardfail.2008.03.004.
    1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469–480. doi: 10.1111/j.1464-5491.2006.01858.x.
    1. Lainscak M, Doehner W, Anker SD. Metabolic disturbances in chronic heart failure: a case for the “macho” approach with testosterone?! Eur J Heart Fail. 2007;9:2–3. doi: 10.1016/j.ejheart.2006.07.006.
    1. Vaz-Pérez A, Doehner W, von Haehling S, Schmidt H, Zimmermann AV, Volk HD, Anker SD, Rauchhaus M. The relationship between tumor necrosis factor-alpha, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol. 2010;141:39–43. doi: 10.1016/j.ijcard.2008.11.146.
    1. von Haehling S, Schefold JC, Lainscak M, Doehner W, Anker SD. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin. 2009;5:549–560. doi: 10.1016/j.hfc.2009.04.001.
    1. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, McMurray JJ. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J. 2007;28:829–835. doi: 10.1093/eurheartj/ehm033.
    1. Haugen E, Furukawa Y, Isic A, Fu M. Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: a hospital cohort study. Int J Cardiol. 2008;125:216–219. doi: 10.1016/j.ijcard.2007.12.002.
    1. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, Okazaki H, Asai M, Nagamachi Y, Maeda N, Shintani Y, Minamino T, Asakura M, Kishimoto I, Funahashi T, Tomoike H, Kitakaze M. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol. 2009;53:2070–2077. doi: 10.1016/j.jacc.2009.02.038.
    1. Sam F, Duhaney TA, Sato K, Wilson RM, Ohashi K, Sono-Romanelli S, Higuchi A, De Silva DS, Qin F, Walsh K, Ouchi N. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology. 2010;151:322–331. doi: 10.1210/en.2009-0806.
    1. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi